

# Targeted biologics for chronic rhinosinusitis with nasal polyps: efficacy-safety comparison of eight monoclonal antibodies via network meta-analysis

## Population



2,034 participants with CRSwNP

## Interventions




8 monoclonal antibodies

**Comparison:** Placebo  
(Standard treatment)  
**Outcomes:** NPS, LMK, UPSIT,  
SNOT-22, NCS, AES  
**Study design:** 16 RCTs

## Eight biologics for CRSwNP: A network Meta-analysis

### Methods

- ✓ Network Meta-Analysis
- ✓ Bayesian Model




(A) NPS



(B) Lund-Mackay



(C) UPSIT



(D) SNOT-22



(E) NCS



(F) AES



## Conclusions

All evaluated biological agents demonstrated efficacy superior to placebo, with IL-4 receptor alpha inhibitors showing the largest and most consistent benefits. All treatments exhibited favorable safety profiles, supporting their use for long-term management of CRSwNP.